A class of Alzheimer’s drugs that have only been available for several years did not appear to have any “clinically meaningful effects,” according to a new review of clinical trial data.
Monoclonal antibodies that target plaque called amyloid beta in the brain showed little impact across 17 trials, Francesco Nonino, a neurologist and epidemiologist who directs the Unit of Epidemiology and Statistics at the IRCCS Institute of Neurological Sciences of Bologna, Italy, and co-authors wrote in the review.
